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Abstract
Background: Acute kidney injury (AKI) is common among intensive care unit (ICU) patients. AKI is highly
heterogeneous, with variable links to poor outcomes. Current approaches to classify AKI severity and identify
patients at highest risk for poor outcomes focus on the maximum change in serum creatinine (SCr) values.
However, these scores are hampered by the need for a reliable baseline SCr value and the absence of a component
differentiating transient from persistent rises in SCr. We hypothesized that identification of resolving or nonresolving
AKI subphenotypes based on the early trajectory of SCr values in the ICU would better differentiate patients at risk of
hospital mortality.
Methods: We performed a secondary analysis of two prospective studies of ICU patients admitted to a
trauma ICU (group 1; n = 1914) or general medical-surgical ICUs (group 2; n = 1867). In group 1, we tested
definitions for resolving and nonresolving AKI subphenotypes and selected the definitions resulting in
subphenotypes with the greatest separation in risk of death relative to non-AKI controls. We applied this
definition to group 2 and tested whether the subphenotypes were independently associated with hospital
mortality after adjustment for AKI severity.
Results: AKI occurred in 46% and 69% of patients in groups 1 and 2, respectively. In group 1, a resolving
AKI subphenotype (defined as a decrease in SCr of 0.3 mg/dl or 25% from maximum in the first 72 h of
study enrollment) was associated with a low risk of death. A nonresolving AKI subphenotype (defined as all
AKI cases not meeting the “resolving” definition) was associated with a high risk of death. In group 2, the
resolving AKI subphenotype was not associated with increased mortality (relative risk [RR] 0.86, 95% CI 0.63–1.17),
whereas the nonresolving AKI subphenotype was associated with higher mortality (RR 1.68, 95% CI 1.15–2.44) even
after adjustment for AKI severity stage.
Conclusions: The trajectory of SCr levels identifies AKI subphenotypes with different risks for death, even
among AKI cases of similar severity. These AKI subphenotypes might better define the patients at risk for
poor outcomes who might benefit from novel interventions.
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Background
Acute kidney injury (AKI) is a heterogeneous syndrome
defined by the Kidney Disease: Improving Global Out-
comes (KDIGO) group as an increase in serum creatin-
ine (SCr) of ≥0.3 mg/dl or >50% from baseline. The
KDIGO group classifies patients from stage 0 (no AKI)
to stage 3 AKI, based on maximum change in SCr or
minimum urine output throughout the hospital stay.
This definition for AKI includes a broad range of under-
lying pathophysiologic processes that would be expected
to have different risks for poor clinical outcomes and
may need to be treated differently. For instance, the
KDIGO AKI definition does not differentiate between
rises in creatinine due to temporary hemodynamic
changes (e.g., volume depletion) versus true parenchymal
injury (e.g., acute tubular necrosis). Even after classifica-
tion by KDIGO severity stage, there is likely to be con-
siderable clinical and biological heterogeneity. These
limitations of the current AKI definition hamper the
ability to better understand the pathophysiology of
AKI and, potentially, the identification of effective
novel therapies [1].
In clinical syndromes such as cancer, acute respiratory
distress syndrome (ARDS), chronic obstructive pulmon-
ary disease (COPD), and asthma, identification of
subphenotypes has led to insights into their pathogenesis
and the development of personalized approaches to care
[2–8]. For example, Calfee et al. showed in patients with
ARDS that indirect or direct lung injury is characterized
by a unique biomarker pattern indicative of endothelial
or epithelial dysfunction, respectively, suggestive of dif-
ferences in the underlying pathobiology leading to these
two forms of ARDS [5]. Additionally, in studies of
asthma and COPD, researchers have employed a broad
panel of clinical factors to identify subphenotypes [6, 8].
In our present study, we used creatinine kinetics to iden-
tify subphenotypes within AKI.
The trajectory of renal dysfunction is a potentially
important and clinically intuitive parameter by which to
understand AKI. Classifying AKI on the basis of trajec-
tory rather than maximal creatinine change gets around
the requirement for a preadmission “baseline” creatinine,
which often is lacking for patients admitted to the inten-
sive care unit (ICU) [9]. Classification based on trajec-
tory also takes into account a patient’s response to early
medical interventions and uses the added information
provided by serial measures of renal dysfunction. Thus,
identification of AKI subphenotypes based on the trajec-
tory of SCr might improve the precision of risk stratifi-
cation and provide more homogeneous groups of AKI
cases.
We hypothesized that classifying patients with AKI
into resolving and nonresolving subphenotypes on the
basis of the trajectory of changes in SCr within the first
72 h of enrollment would result in groups with low and
high associations with death, respectively. We also
hypothesized that trajectory-based classification of AKI
would be strongly linked to risk of death even after
accounting for KDIGO severity stage.
Methods
Study design
We performed a secondary analysis of two independent,
prospectively collected datasets (a single-center cohort
and a multicenter sample) of patients admitted to the
ICU. The single-center cohort (group 1; n = 1914) com-
prised patients with severe traumatic injury resulting in
ICU admission between 2003 and 2005 [10]. The multi-
center sample (group 2; n = 1867) was assembled as part
of the identification of SNPs Predisposing to Altered
ALI Risk (iSPAAR) study, a genome-wide case-control
study of the risk for ARDS. The dataset included sub-
jects at risk for ARDS enrolled from ICUs as part of the
Molecular Epidemiology of Acute Respiratory Distress
Syndrome (MEA) at the Massachusetts General Hospital
[11] and subjects with ARDS enrolled by the National
Heart, Lung, and Blood Institute (NHLBI) ARDS
Network [12–15]. In both groups, patients with end-
stage renal disease prior to admission were excluded. Of
2953 patients in group 1, 1012 were excluded because
they were younger than 18 years of age, missing transfer
data or receiving outpatient dialysis. Of 2236 patients in
group 2, 369 were excluded because they were younger
than 18 years of age, missing day 0 or day 1 creatinine
values, and receiving outpatient dialysis. A flowchart of
patients included in the study is provided in Additional
file 1: Figure S1. The median number of SCr values was
greater than 3.5.
Data collection and measurement
AKI and stage of AKI were determined by changes in
creatinine in accordance with the KDIGO criteria SCr
thresholds for AKI during the first 72 h after study
enrollment. We restricted our analysis to the first 72 h
of ICU stay in an effort to focus on AKI due to the
critical illness leading to ICU admission and to allow
comparison with prior literature [16, 17]. We used SCr
values obtained as part of clinical care, and the study did
not mandate timing of measurement of SCr values. We
did not include urine output in our determination of
AKI, given the heterogeneity of urine output recordings
and the high degree of missing data. We did not have
access to preadmission baseline creatinine values for
these subjects. Therefore, we set the baseline creatinine
as the nadir observed in the first 72 h. AKI and severity
were determined on the basis of maximal difference be-
tween the nadir creatinine and the maximal creatinine
over this period.
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We tested four definitions for the subphenotypes of
resolving or nonresolving AKI. Patients were classified
as resolving if they had a trajectory of SCr that was
improving. All patients who did not meet the resolving
criteria were classified as nonresolving. The SCr criteria
for these definitions were based on a clinically meaning-
ful change that reflected the magnitude of creatinine
changes present in the KDIGO definition. We also
explored variations of the definition for resolution that
employed higher and lower changes in creatinine. We
applied these definitions to group 1 and then compared
hospital mortality for each set of resulting AKI subphe-
notypes (resolving/nonresolving) with that observed in
patients without AKI. The definition demonstrating the
largest separation in relative risk (RR) for death between
resolving and nonresolving subphenotypes was carried
forward to group 2.
Hospital mortality was defined as death prior to
hospital discharge. Patients who died with less than two
creatinine values were excluded. Hospital- and ICU-free
days were defined as days free of the hospital and the
ICU in the first 28 days after ICU admission. If a patient
died within 28 days, then that patient had 0 ICU- or
hospital-free days.
Statistical analysis
We report continuous variables as means ± standard de-
viations and categorical variables as counts and percent-
ages. Approximately 5% or less of the study participants
were missing data on diabetes mellitus, cirrhosis, and va-
sopressors. For the regression analyses, data for partici-
pants with missing values for these covariates were
imputed using chained equations and combined using
Rubin rules [18]. No imputations were completed for
exposure or outcome measures. Spaghetti plots were
used to describe the longitudinal creatinine measure-
ments and trajectories within each subphenotype
designation.
RR regression was used to model the probability of
death as a function of covariates using a generalized lin-
ear model with log-link and binomial error distribution
[19]. In cases in which the model failed to converge with
the binomial error (about 10% of the models), we
substituted Gaussian error and used robust standard
error estimates. The risk of death of each AKI subphe-
notype was compared with that of patients with no AKI.
In group 1, we used unadjusted RR regression of the
AKI subphenotype definitions and mortality. The defin-
ition that identified the greatest difference in risk of
mortality between AKI subphenotypes was applied to
group 2. In group 2, the first adjusted model included
baseline age, sex, and race. Subsequent models added
variables to the basic adjustment model that may con-
found or mediate the associations of interest. These
variables were decided a priori on the basis of biological
plausibility and prior literature [20–23]. The second
model added body mass index, diabetes mellitus, Sepsis-
related Organ Failure Assessment score (omitting
creatinine), vasopressor use, sepsis (defined as two sys-
temic inflammatory response syndrome criteria and a
suspected source of infection), and the third model
added maximum KDIGO stage of AKI during the first
72 h of hospital admission. Maximum KDIGO stage was
included as an ordinal variable.
We conducted sensitivity analyses to evaluate whether
associations between AKI subphenotype and mortality
were robust within each KDIGO stage of AKI and used
the likelihood ratio test to evaluate the statistical signifi-
cance of the interaction. We used logistic regression
incorporating an interaction term for the product of the
maximum KDIGO stage and AKI subphenotype (i.e., no
AKI, resolving and nonresolving). We also evaluated the
association of timing of peak of SCr in the resolving
subphenotype and mortality. Statistical analyses were
conducted using Stata 13.0 software (StataCorp, College
Station, TX, USA).
Results
Clinical data within groups 1 and 2
Baseline clinical data for patients in group 1 (trauma)
and group 2 (mixed medical-surgical) are presented in
Tables 1 and 2, respectively. Several differences between
the two groups were noted. Group 1 tended to be youn-
ger and consisted of more patients transferred from
another facility. Group 2 had more patients admitted
with sepsis and requiring vasopressors early in their hos-
pital stay. The populations in each group had a similar
number of patients requiring mechanical ventilation.
The trauma group had a mean Injury Severity Score of
23.6 and the medical-surgical mixed-sample group had a
mean Acute Physiology and Chronic Health Evaluation
III (APACHE III) score of 74. The percentage of patients
with at least stage 1 AKI per KDIGO thresholds was
46% in group 1 and 69% in group 2. The proportion of
patients with KDIGO stage 2 or 3 AKI among all
patients with AKI was lower in group 1 (9%) than in
group 2 (27%).
Identification of subphenotypes in group 1
We tested four definitions of AKI subphenotypes in
group 1 (trauma) and assessed the risk of death for
each pair of subphenotypes relative to those without
AKI (Additional file 1: Table S1). Definition 2 best
separated the risk of death associated with the two
AKI subphenotypes. The estimated increase in risk of
death for the nonresolving subphenotype relative to
patients without AKI was large (RR 2.95, 95% CI
2.08–4.19). In contrast, the resolving subphenotype
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had a markedly lower estimated effect on risk of
death (RR 1.54, 95% CI 1.13–2.11) (Tables 3 and 4).
Definition 2 criteria for the resolving subphenotype
were a 0.3-mg/dl and/or 25% decrease in SCr from
the maximum value during the first 72 h after study
enrollment. Patients with AKI who did not meet
these criteria for the resolving subphenotype were
classified as having the nonresolving subphenotype. A
graphical representation with a trend line of patients
with resolving and nonresolving subphenotypes of
AKI in group 1 is shown in Fig. 1. This graph shows
the consistency in creatinine trajectories within the
resolving and nonresolving AKI subphenotypes.
Versions of Additional file 1: Tables S1 and S2
including the AKI subphenotypes are provided in
Additional file 1: Tables S2–S4.
AKI subphenotypes and risk of mortality in group 2
We applied the subphenotype criteria in definition 2 to
subjects in group 2. Similar to our findings in group 1,
we found that mortality was higher for patients with a
nonresolving AKI subphenotype (26%) than for those
with a resolving AKI subphenotype (13%), and mortality
for both was numerically higher than that observed for
subjects without AKI (11%). The subjects with the non-
resolving subphenotype experienced fewer hospital and
ICU-free days than those with the resolving subpheno-
type (Tables 3 and 4). Increasing severity of AKI was also
Table 1 Patient characteristics in group 1 (trauma)
Clinical variables No acute kidney injury Acute kidney injury Total AKI versus no AKI p value
Total 1037 877 1914
Baseline demographics
Age, years 36.8 ± 20.7 41.4 ± 19.9 38.9 ± 20.4 <0.01
Male sex, n (%) 678 (65) 691 (79) 1369 (72) <0.01
Body mass index, kg/m2 25.6 ± 9.2 27.6 ± 6.8 26.5 ± 8 <0.01
Race, n (%)
White 793 (77) 686 (78) 1479 (77) 0.96
Hispanic 91 (9) 55 (6) 146 (8)
Black 64 (6) 56 (6) 120 (6)
Other 65 (6) 60 (7) 125 (7)
Unknown 24 (2) 20 (2) 44 (2)
Comorbidities, n (%)
Diabetes mellitus 34 (5) 61 (7) 95 (7.5) 0.01
Cerebrovascular disease 171 (17) 227 (26) 398 (21) <0.01
Chronic kidney disease 4 (<1) 14 (2) 18 (1) 0.02
Injury Severity Score 23.1 ± 10.0 24.3 ± 10.2 23.6 ± 10.2 0.01
ICU events, n (%)
Mechanical ventilation 701 (68) 657 (75) 1358 (71) <0.01
Sepsis 235 (23) 236 (27) 471 (25) 0.01
Septic shock 30 (3) 70 (8) 100 (5) <0.01
Vasopressors 89 (9) 133 (15) 222 (12) <0.01
Admission status, n (%)
Direct 719 (69) 645 (74) 1364 (71) <0.01
Transfer 318 (31) 232 (26) 550 (29)
Unknown 4 (<1) 1 (<1) 5 (<1)
KDIGO stage of acute kidney injury, n (%)
Stage 0 1037 (100) 0 1037 (54)
Stage 1 0 807 (92) 807 (42)
Stage 2 0 48 (5) 48 (3)
Stage 3 0 22 (3) 22 (1)
AKI Acute kidney injury, ICU Intensive care unit, KDIGO Kidney Disease: Improving Global Outcomes
Data shown as mean ± standard deviation, n (%) as appropriate
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Table 2 Patient characteristics in group 2 (mixed medical-surgical)
Clinical variables No acute kidney injury Acute kidney injury Total AKI versus no AKI p value
Total 573 1294 1867
Baseline demographics
Age, years 56.8 ± 16.8 59.8 ± 18 58.9 ± 18 <0.01
Male sex, n (%) 246 (43) 543 (42) 794 (43) 0.78
Body mass index, kg/m2 27.5 ± 7.7 28.2 ± 7.5 27.9 ± 7.6 0.09
Race, n (%)
White 573 (100) 1294 (100) 1867 (100) 1
Comorbidities, n (%)
Diabetes mellitus 95 (17) 331 (26) 426 (23) <0.01
SOFA score 7.0 ± 2.3 8.8 ± 2.9 8.3 ± 2.8 <0.01
SOFA without renal component 6.9 ± 2.2 7.7 ± 2.5 7.5 ± 2.5 <0.01
APACHE III score 64 ± 24.6 78 ± 26.8 74 ± 26.8 <0.01
ICU events, n (%)
Mechanical ventilation 416 (78) 909 (70) 1325 (77) <0.01
Sepsis 325 (56) 877 (68) 1202 (64) <0.01
Vasopressors 134 (35) 571 (44) 705 (48) <0.01
Diagnosis of ARDS 306 (53) 700 (37) 1006 (54) <0.01
Clinical risk for ARDS, n (%)
Pneumonia 298 (52) 702 (54) 1000 (54) 0.37
Sepsis 366 (64) 1006 (78) 1372 (73) <0.01
Aspiration 74 (13) 158 (12) 232 (12) 0.75
Trauma 57 (10) 86 (7) 143 (8) 0.01
Other 23 (4) 31 (2) 54 (3) 0.06
Admission status, n (%)
Direct 518 (90) 1192 (92) 1710 (92) 0.21
Transfer 55 (10) 102 (8) 157 (8)
KDIGO stage of acute kidney injury, n (%)
Stage 0 573 (100) 0 573 (31)
Stage 1 0 944 (73) 944 (51)
Stage 2 0 165 (13) 165 (9)
Stage 3 0 185 (14) 185 (10)
Abbreviations: AKI Acute kidney injury, APACHE III Acute Physiology and Chronic Health Evaluation III, ARDS Acute respiratory distress syndrome, ICU Intensive care
unit, KDIGO Kidney Disease: Improving Global Outcomes, SOFA Sepsis-related Organ Failure Assessment
Data shown as mean ± standard deviation, n (%) as appropriate
Table 3 Clinical outcomes in group 1 (trauma)
AKI Severity AKI Subphenotype
Outcomes No AKI Stage 1 Stage 2 Stage 3 Resolving Nonresolving
Number of patients 1037 807 48 22 647 230
Mortality, n (%) 72 (7) 102 (12) 8 (16) 6 (27) 72 (11) 42 (20)
Hospital-free days, 28 days, n (IQR) 16 (5–22) 11 (0–19) 8 (0–16.5) 0.5 (0–12) 11 (0–18) 4 (0–18)
ICU-free days, 28 days, n (IQR) 24 (17–26) 21 (7–25) 16.5 (0–24) 11.5 (0–23) 21 (9–24) 15 (0–25)
AKI Acute kidney injury, ICU Intensive care unit
Data are presented as count (percent) or median (interquartile range [IQR]), unless otherwise indicated
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associated with higher mortality and fewer hospital- and
ICU-free days in group 2. The mean ± standard deviation
of APACHE III scores in the resolving AKI group was
78 ± 26, and in the nonresolving AKI group it was 78.9
± 28. The rates of mechanical ventilation and vasopres-
sor use were similar between the AKI subphenotypes.
Using multivariable logistic regression, we built models
in a stepwise fashion to evaluate the association of
trajectory with hospital mortality (Table 5). Model 2 in-
cluded patient demographics, comorbidities, and ICU
factors. In model 2, a nonresolving subphenotype of AKI
was associated with a 50% increase in RR for in-hospital
mortality compared with patients without AKI (RR 1.52,
95% CI 1.13–2.05). A resolving subphenotype compared
with no AKI was not associated with mortality (RR 0.86,
95% CI 0.63–1.17). Next, we tested whether the associ-
ation between AKI subphenotypes and mortality was in-
dependent of maximal AKI stage. We added AKI stage
to the multivariable model (model 3) and found that
patients with a nonresolving subphenotype of AKI
still had a 68% higher risk of death (RR 1.68, 95%
CI 1.15–2.44).
Risk of mortality by AKI subphenotype within KDIGO
stages in group 2
We found that, within every KDIGO AKI stage, the
subjects with the nonresolving subphenotype had
higher mortality than those with the resolving sub-
phenotype (p for interaction = 0.035) (Table 6). For
example, among subjects with KDIGO stage 1 AKI,
those with the nonresolving subphenotype had more
than twice the risk of death (RR 2.06, 95% CI 1.52–
2.80) compared with a resolving subphenotype.
Timing of SCr peak in the resolving AKI subphenotype
and risk of mortality
We completed additional sensitivity analyses to evaluate,
in the subgroup of patients with a resolving AKI
Table 4 Clinical outcomes in group 2 (mixed medical-surgical)
AKI severity AKI subphenotype
Outcomes No AKI Stage 1 Stage 2 Stage 3 Resolving Nonresolving
Number of patients 573 944 165 185 875 419
Mortality, n (%) 62 (11) 148 (16) 35 (21) 39 (21) 115 (13) 107 (26)
Hospital-free days, 28 days, n (IQR) 19 (11–24) 17 (7–23) 16 (1–22) 13 (0–20) 17 (8–23) 14 (0–21)
ICU-free days, 28 days, n (IQR) 21 (12–25) 20 (11–24) 18 (4–24.5) 18 (0–24) 21 (13–25) 17 (0–23)
AKI Acute kidney injury, ICU Intensive care unit
Data are presented as count (percent) or median (interquartile range [IQR]), unless otherwise indicated
A B
Fig. 1 Diagram of the trajectory of patients with acute kidney injury (AKI) in the resolving and nonresolving subphenotype groups.
Graphical representation of serum creatinine (SCr) trajectory in AKI subphenotypes. Spaghetti plots with trend lines of serial SCr values
obtained over the first 72–96 h of admission in subjects exhibiting a resolving AKI subphenotype and b nonresolving AKI subphenotype
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subphenotype, if the day of peak in SCr influenced the
association with mortality. The total number of patients
in group 2 with a resolving AKI subphenotype was 914.
Of these 914 patients, 517 had an SCr peak on day 0,
239 peaked on day 1, 117 peaked on day 2, and 41
peaked on day 3. The mortality ranged from 11% if the
SCr peaked on day 0 to 14% if the peak was on day 2 or
on day 3 (Additional file 1: Table S4).
Discussion
In two distinct, large, heterogeneous ICU populations,
we demonstrated that the trajectory of SCr defines sub-
phenotypes of AKI and that these subphenotypes are in-
dependently associated with hospital mortality, length of
hospital stay, and length of ICU stay. Despite significant
differences in baseline clinical characteristics, etiologies
for renal dysfunction, and ICU-level therapies between
group 1 (trauma) and group 2 (mixed medical-surgical),
the association between AKI subphenotypes and short-
term clinical outcomes persisted. Critically ill patients
with a nonresolving subphenotype compared with no
renal dysfunction had a greater than 60% increased risk
of hospital mortality. Additionally, patients with a
resolving subphenotype had the same risk of death as
those having no AKI. Of even greater interest, when we
controlled for KDIGO severity of AKI, both AKI sub-
phenotypes maintained their associations with hospital
mortality. Notably, even among patients with KDIGO
stage 1 AKI, the nonresolving subphenotype was asso-
ciated with double the risk of death compared with
the resolving subphenotype. These findings show that
there exists considerable variability in risk for poor
outcomes within the KDIGO stages of AKI and that
even relatively small decreases in SCr from the max-
imal value have important implications for hospital
outcomes.
Our findings extend and clarify those of prior stud-
ies seeking to subclassify patients with AKI. In previ-
ous studies, researchers evaluated the relationship
between duration of AKI (transient versus persistent)
and hospital mortality but found contradictory results
[16, 17, 24]. In two studies, researchers found that
separating patients on the basis of duration of AKI
between transient (less than 72 h) and persistent
Table 5 Adjusted relative risk for hospital mortality by trajectory and KDIGO classification in group 2 (mixed medical-surgical)
Relative risk (95% CI)
Participants Events, n (%) Model 1 Model 2 Model 3
No AKI 573 62 (10.8) 1.00 (reference) 1.00 (reference)
KDIGO AKI stage
Stage 1 944 148 (15.7) 1.27 (0.96–1.69) 1.05 (0.78–1.43) –
Stage 2 165 35 (21.2) 1.75 (1.19–2.57) 1.23 (0.85–1.78) –
Stage 3 185 39 (21.1) 1.68 (1.14–2.48) 1.2 (0.84–1.73) –
Subphenotype
Resolving 875 115 (13.1) 1.05 (0.78–1.43) 0.86 (0.63–1.17) 0.95 (0.64–1.41)
Nonresolving 419 107 (25.5) 2.04 (1.52–2.75) 1.52 (1.13–2.05) 1.68 (1.15–2.44)
AKI Acute kidney injury, KDIGO Kidney Disease: Improving Global Outcomes
Model 1: Age, sex, race
Model 2: Body mass index, diabetes mellitus, Sepsis-related Organ Failure Assessment score, vasopressor use, sepsis
Model 3: Maximum KDIGO stage of AKI
Table 6 Adjusted relative risk for in-hospital mortality within KDIGO acute kidney injury stage by trajectory of acute kidney injury
within group 2
KDIGO AKI stage AKI Subphenotype n (%) Deaths, n (%) RRa (95% CI)
No AKI – 573 (31) 62 (10.8)
Stage 1 Resolving 610 (33) 70 (11.5) 1.0 (reference)
Nonresolving 334 (17) 78 (23.4) 2.06 (1.52–2.80)
Stage 2 Resolving 131 (7) 21 (16.0) 1.0 (reference)
Nonresolving 34 (2) 14 (41.2) 2.41 (1.36–4.29)
Stage 3 Resolving 134 (7) 24 (17.9) 1.0 (reference)
Nonresolving 51 (3) 15 (29.4) 1.59 (0.87–2.92)
AKI Acute kidney injury, KDIGO Kidney Disease: Improving Global Outcomes, RR Relative risk
p for interaction between KDIGO stage and trajectory on risk of death: p = 0.035
a Adjusted for age, sex, race (all white), body mass index, diabetes mellitus, Sepsis-related Organ Failure Assessment without renal component,
vasopressors, sepsis
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(greater than 72 h) did not lead to the identification
of patients at increased risk for mortality [16, 17]. In
contrast, researchers in a third study of patients ex-
periencing AKI after elective surgery found that a
group of patients with a long duration of AKI were at
higher risk of death than a group with a short AKI
duration [25]. One potential explanation for these
conflicting results is that the authors mandated that
the baseline creatinine be based on an outpatient
value, which is often unavailable in ICU patients [9].
For baseline values that were missing, researchers in
these studies used mathematical formulas to impute
this baseline SCr value. Given that these formulas
were derived from relatively healthy outpatients in the
steady state [26] with a “normal” expected glomerular
filtrate rate, the application of these formulas to crit-
ically ill patients may lead to significant inaccuracies
[27, 28]. In our present study, we sought to address
this problem by developing an approach to subclassify
AKI on the basis of patterns of SCr values after ICU
admission, obviating the need for an outpatient or
premorbid SCr value.
Our approach shows robust associations between nonre-
solving AKI and poor hospital outcomes in two large ICU
cohorts. We selected the definition used to identify the two
AKI subphenotypes—resolving and nonresolving—in a
cohort of patients with a low prevalence of preexisting kid-
ney disease and in whom the temporal relationship be-
tween injury and development of AKI was known. We
then applied this definition for AKI subphenotypes to a
considerably more diverse ICU population (mixed
medical-surgical population). Markers of severity of illness,
such as APACHE III score, vasopressor use, and mechan-
ical ventilation, did not differentiate the AKI subpheno-
types on ICU admission. Thus, we have identified a novel
marker for risk of death over and above traditional risk fac-
tors for AKI and even well-established AKI severity scores.
Of interest, three of the four AKI subphenotype defi-
nitions tested in group 1 showed differential risks for
mortality. This suggests that the optimal definition
may remain undetermined. Nonetheless, our work
clearly shows that patients with a rapidly improving
SCr have a very different outcome from a nonresol-
ving SCr.
There are several ways in which classifying patients
by AKI subphenotypes could be useful. First, refining
the AKI phenotype could aid studies evaluating the
pathophysiology of AKI by providing a more uniform
study population. For instance, identifying AKI
subphenotypes might enrich genetic studies for a
particular pathologic subtype of AKI, thus reducing
misclassification and improving the power to identify
genetic risk factors associated with the development
of AKI. Second, knowledge of AKI subphenotypes
that are associated with differential risk of clinical
outcomes could aid in triage decisions for severely ill
patients. Third, enrollment in clinical trials could be
directed at subgroups of patients most at risk of poor
outcomes who might benefit from a novel therapeutic
intervention. Fourth, existing biomarkers, such as
neutrophil gelatinase-associated lipocalin, have had
mixed results in identifying patients with AKI. In the
cohorts studied, the KDIGO stage of AKI influenced
the effectiveness of biomarkers to predict the devel-
opment of AKI with lower test performance charac-
teristics in patients with less severe AKI [29–31].
Because the trajectory of SCr identifies patients with
increased risk of poor clinical outcomes, it is possible
that identifying AKI subphenotypes may improve bio-
marker performance. Grouping patients with a resolv-
ing versus nonresolving trajectory increases the
heterogeneity of AKI and likely limits biomarker
development.
Our study has some limitations. First, we did not
have data on urine output, which can define an AKI
event by KDIGO criteria. The inclusion of urine
output may have increased the number of subjects
classified as AKI cases and improved our ability to
categorize AKI [32]. However, given that our defini-
tions for the subphenotypes were based on the trajec-
tory of SCr values, a better marker of true glomerular
filtration rate and risk of death [26, 33], it is unlikely
that our findings would have been different to a
meaningful degree. Second, to determine severity of
AKI, we used the nadir of SCr rather than a pread-
mission baseline value. Prehospital SCr values are
often lacking in ICU patients, particularly during the
early part of their admission, and thus an approach
that bypasses the requirement for this information
could allow for a more timely identification of AKI
subphenotypes. Prehospital SCr values may have
improved the accuracy of the KDIGO severity of AKI,
but it is unlikely to have influenced the association of
trajectory with outcomes. Additionally, if we had used
prehospital SCr, then fluid administration in the
emergency room or ICU may have created a dilution
effect and decreased the incidence of AKI. In con-
trast, using a nadir of SCr overcomes this limitation
by accounting for changes in SCr secondary to fluid
administration. Third, group 1 included few patients
with KDIGO AKI stage 2 or 3. The lack of these
stages of AKI may limit the generalizability of
trajectory-based findings to a trauma population with
severe AKI. Fourth, previous studies have compared
patients with and without AKI and have found an
association with fluid accumulation and mortality in
AKI [34, 35]. While most patients in the study were
likely vigorously hydrated early in their ICU care, in
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accordance with ICU practice, we lacked accurate
fluid balance data. Thus, it is unknown how fluid
balance was associated with AKI subphenotype during
a patient’s hospital stay.
Our study has several strengths. First, our defini-
tions of AKI subphenotypes are based on changes in
serial SCr values that are widely available in many
existing ICU datasets. This will allow our subpheno-
type definitions to be quickly determined in large
numbers of critically ill patients and their relation-
ships with outcomes to be assessed. Furthermore,
future application of our definitions to prospectively
identify AKI subphenotypes should be straightforward.
Second, we observed large and robust increases in
risk of death associated with the nonresolving AKI
subphenotype that were independent of the most
widely established measure of AKI severity, the
KDIGO staging system. This suggests that our
approach could add value to the current classification
schemes for AKI. Third, we used a large and diverse
set of ICU patients who ranged from victims of major
trauma to patients with severe pneumonia enrolled in
randomized clinical trials of ARDS. Furthermore, the
patients in group 1 were racially diverse. These fac-
tors suggest that our findings will be generalizable to
other critically ill patient populations. Our results
need to be validated in additional larger multicenter
cohorts of critically ill patients.
Conclusions
We identified two distinct subphenotypes of AKI that
are associated with different risks for hospital mortal-
ity. These subphenotypes also identify subjects with
differences in risk for other short-term outcomes,
including prolonged course in the ICU and time
requiring mechanical ventilator support. Our observa-
tions should prompt future research to molecularly
characterize these subphenotypes and to evaluate
predictive biomarkers that might enable earlier identi-
fication of AKI subphenotypes. Refining the classifica-
tion of AKI in ICU populations will allow recognition
of patients at high risk of poor outcomes who might
be targeted for enrollment in clinical trials, improve
triage decisions, and focus the search for genetic risk
factors.
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